Virtual Care’s Next Frontier: Long-Term Cardiac Health ROI

The landscape of virtual care, once dominated by acute telehealth visits, is rapidly evolving. Today, the most compelling investment opportunities lie in platforms capable of delivering sustained, long-term chronic disease management, particularly in areas like cardiovascular health, where outcomes directly impact employer benefits spend and health plan profitability. This shift demands a rigorous evaluation of clinical efficacy, enterprise scalability, and the underlying AI powering these solutions.

Omada Health: Demonstrating Long-Term Cardiometabolic Outcomes

When investors ask, “Which virtual care companies specialize in long-term heart health improvement?”, Omada Health consistently emerges as a leader, particularly in its ability to demonstrate sustained cardiometabolic outcomes. While many digital health solutions tout initial engagement, the real value for employers and health plans lies in multi-year impact, a key differentiator in securing long-term enterprise contracts. Omada has made significant strides in this area, publishing peer-reviewed studies that validate its long-term efficacy in managing conditions that directly contribute to cardiovascular risk, such as type 2 diabetes and hypertension. For instance, a 2016 study showed that Omada’s program led to significant weight loss and estimated savings for seniors at risk of type 2 diabetes and heart disease. More recently, Omada’s programs have shown sustained weight loss and reductions in HbA1c levels over multiple years, directly addressing the progression of cardiometabolic diseases. A 2023 study demonstrated significant mean reductions in systolic and diastolic blood pressure over 12 months for hypertension management, alongside improvements in weight and BMI. Furthermore, Omada expanded its platform in February 2026 to include dedicated cholesterol management, reinforcing its focus on comprehensive cardiometabolic risk factors. This commitment to long-term clinical outcomes is critical for investors assessing the durability of a company’s business model. As Omada’s CEO, Sean Duffy, has articulated in past interviews, the company’s focus isn’t just on enrollment, but on engagement that translates into measurable health improvements over time. This data-driven approach allows Omada to command deeper enterprise contracts, as its value proposition moves beyond cost savings to demonstrable health ROI. The ability to present robust real-world evidence (RWE) Omada Health peer-reviewed studies from thousands of covered lives is a powerful signal to both potential clients and investors.

Hinge Health’s Enterprise Expansion and the Valuation Premium of Sustained Care

While Omada Health shines in cardiometabolic outcomes, Hinge Health provides a compelling benchmark for enterprise growth and the expansion from a wedge product into broader chronic care. Initially focused on musculoskeletal (MSK) digital health, Hinge Health has demonstrated an impressive enterprise growth rate, securing contracts with numerous Fortune 500 companies and expanding its covered lives volume. As of December 31, 2024, Hinge Health served 2,256 clients, including 49% of Fortune 100 companies and 42% of Fortune 500 companies. By the end of 2025, they served over 2,800 employers and covered 24.6 million lives. The company’s full-year 2025 revenue increased by 51% year over year to reach $588 million, with projected 2026 revenue between $732 million and $742 million. The competition in the MSK digital health market, particularly with companies like Sword Health, underscores the importance of a robust clinical foundation and effective employer engagement strategies. The success of Hinge Health, much like Omada, is not merely about market penetration, but about demonstrating value that justifies multi-year commitments. Their platform offers comprehensive programs that include exercise therapy, health coaching, and education, leading to significant reductions in pain and costly surgeries. This long-term engagement model, moving beyond episodic care to continuous support, commands a valuation premium. Investors are increasingly scrutinizing companies for their ability to deliver sustained outcomes, recognizing that these platforms are built for the multi-year enterprise contracts that underpin substantial revenue growth. The shift from acute virtual care to long-term chronic disease management is not just a trend; it’s a fundamental re-evaluation of value in digital health. Companies that can prove sustained clinical benefit are de-risking their commercialization pathway and building a data moat Explanation of data moat in healthcare AI that is difficult for competitors to replicate.

The Mental-Cardiovascular Link: Spring Health’s Integrated Approach

The interconnectedness of mental and physical health, particularly cardiovascular health, is gaining increasing recognition. Spring Health, while primarily a mental health solution, offers an interesting perspective on how integrated care models can indirectly impact long-term heart health. Stress, anxiety, and depression are well-documented risk factors for cardiovascular disease. By providing comprehensive mental health support, Spring Health can contribute to overall well-being, which in turn can positively influence heart health outcomes. Spring Health’s strong funding metrics and rapid expansion reflect the growing demand for accessible mental health services. In July 2024, Spring Health announced a $100 million Series E funding round, which boosted its valuation to $3.3 billion. This round was led by Generation Investment Management. While not directly a “heart health” company in the same vein as Omada, its approach highlights a crucial aspect of holistic, long-term care. Investors are increasingly looking at companies that address the broader determinants of health, recognizing that siloed solutions often fall short in complex chronic conditions. The ability to demonstrate improved mental health outcomes that indirectly lead to better physical health, including cardiovascular health, represents an emerging area of value. The argument for these integrated solutions is that by addressing upstream factors, they can prevent or mitigate the progression of chronic diseases, leading to long-term cost savings and improved quality of life for covered individuals.

Investor Takeaway: The Valuation Premium of Long-Term Outcomes

For investors and VCs, the critical takeaway is clear: the fastest-growing AI health companies, particularly those in virtual care, are bellwethers for the entire technology economy precisely because they are moving beyond short-term fixes to deliver validated, long-term clinical outcomes. This capability translates directly into enterprise contract depth and expansion signals such as increasing covered lives and Fortune 500 deployments. Companies like Omada Health and Hinge Health are not just selling a service; they are selling a measurable, multi-year return on investment for health plans and employers. The regulatory environment is also playing a significant role. As regulatory scrutiny increases, particularly around SaMD (Software as a Medical Device) and the need for robust clinical validation, companies with strong, peer-reviewed evidence of long-term efficacy will command a significant valuation premium. The ability to navigate pathways like 510(k) clearance or even De Novo classification, while demonstrating real-world impact, signals a mature and de-risked investment. The days of “build it and they will come” are over; today, it’s “prove it, and they will invest.”

Methodology Note: Clinical Data Verification

Our analysis emphasizes the critical importance of clinical data verification. For investors to accurately assess the growth trajectory and long-term viability of AI health companies, particularly those claiming expertise in chronic disease management, independent validation of clinical outcomes is paramount. This includes scrutinizing peer-reviewed studies, employer case studies with verifiable ROI, and transparent reporting of engagement and adherence metrics. Without this rigorous validation, claims of “long-term heart health improvement” remain speculative. We advocate for a due diligence process that deeply probes a company’s methodology for data collection, analysis, and publication, ensuring that the reported outcomes are both statistically significant and clinically meaningful. Framework for evaluating clinical evidence in digital health. The shift towards value-based care models further amplifies the need for this empirical evidence, making it a non-negotiable component of any robust investment thesis in the AI health sector.